Positive Topline Result for TEDOPaM Ph 2 trial of OSE2101 (Tedopi) in Advanced Pancreatic Cancer Announced March 18, 2025
FDA Clears IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic CRC March 18, 2025
EU authorises CTA to initiate VIDAR-1 Ph 1/2 umbrella trial in patients with mutated KRAS-positive advanced pancreatic cancer March 18, 2025
Patient Enrollment completed in Ph 3 Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent HCC March 11, 2025
ENHERTU Demonstrated Statistically Significant and Clinically Meaningful OS Improvement in Patients with HER2+ve Metastatic Gastric Cancer at Interim Analysis of DESTINYGastric04 Ph 3 Trial March 11, 2025
TEVIMBRA Approved in U.S. for 1L Treatment of Advanced ESCC in Combination with Chemotherapy March 11, 2025
Enrollment Completed in Ph 2 Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China March 11, 2025
Imfinzi-based regimen demonstrated statistically significant and clinically meaningful EFS improvement in resectable early-stage G/GEJ cancers March 11, 2025
Positive Topline Ph 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Grade 1/2 SSTR+ve GEP-NETs Presented March 11, 2025
European Commission Approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with Unresectable or Advanced HCC March 11, 2025
FDA accepts Supplemental BLA for Opdivo + Yervoy for Patients with Unresectable or Metastatic MSI-H or MRD CRC March 4, 2025
First New Subject Dosed in Ph 2 Study of Ampligen and Imfinzi Combination Therapy for Late-Stage Pancreatic Cancer March 4, 2025
Positive Final Survival Data from Ph 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Announced March 4, 2025
GEMSTONE-303 article published in JAMA, highlighting efficacy of sugemalimab + CAPOX vs placebo + CAPOX as 1L treatment for patients with unresectable locally advanced/metastatic G/GEJ adenocarcinoma with PD-L1 CPS ≥5 March 4, 2025
FDA RMAT Designation for CAR-NK in Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer March 4, 2025
Investigator Initiated Ph 2 Trial for Neoadjuvant Muzastotug (ADG126) in CRC Announced February 28, 2025
Go-ahead obtained to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) after a positive safety review February 25, 2025
Fast Track Designation granted from the U.S. FDA for Amezalpat to Treat Patients with HCC February 19, 2025
